Microbot Medical Launches Full Market Release of LIBERTY System in the U.S.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 13 2026
0mins
Should l Buy MBOT?
Microbot Medical announced that it has successfully executed its limited market release and will commence the full market release of its LIBERTY endovascular robotic system in the U.S. as planned. To date, LIBERTY has been adopted by multiple healthcare systems with dozens of hospitals in their networks. The company stated it is showcasing the system at the Society of Interventional Radiology Annual Scientific Meeting to further educate physicians and accelerate market adoption. "We successfully achieved our goals for the limited market release of the LIBERTY System, including its adoption by leading hospitals across multiple peripheral procedures, giving us the momentum to commence, as planned, the full market release at the SIR conference," said Harel Gadot, chairman and CEO. "It's exciting to see the level of enthusiasm among our existing customers, first when they initially use LIBERTY, utilizing it across multiple procedures, and then as they expand it to other hospital sites within their network."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MBOT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MBOT
Wall Street analysts forecast MBOT stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.340
Low
5.50
Averages
8.75
High
12.00
Current: 2.340
Low
5.50
Averages
8.75
High
12.00
About MBOT
Microbot Medical Inc. is a pre-commercial stage medical technology company. It has developed the single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. It specializes in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. It eliminates the need for extensive capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. Its addressable markets for the LIBERTY Endovascular Robotic Surgical System include the peripheral interventional radiology, interventional cardiology and interventional neuroradiology markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Microbot Medical Announces Full Market Release of LIBERTY System
- Market Release Highlights: Microbot Medical showcased the Full Market Release of its LIBERTY® Endovascular Robotic System at the 25th Annual Needham Virtual Healthcare Conference, marking a significant advancement in the medical device sector that is expected to enhance its market share and brand influence.
- CEO Presentation: CEO Harel Gadot will present live on April 15, 2026, at 10:15 AM ET, discussing the company's strategic positioning and growth opportunities, emphasizing the LIBERTY system's importance in addressing physician radiation risks and staffing challenges.
- Technological Innovation: The LIBERTY system is the world's first FDA-cleared single-use, remotely operated robotic solution designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain on physicians, which is expected to improve safety and efficiency in medical procedures.
- Investor Engagement: The Microbot team will engage in pre-scheduled one-on-one meetings with healthcare-focused institutional investors, showcasing its innovative capabilities in medical robotics and market potential, thereby attracting investor interest and driving company growth.
See More
Microbot Medical Launches LIBERTY System Successfully
- Successful Market Release: Microbot Medical announced the successful execution of its Limited Market Release (LMR) for the LIBERTY® Endovascular Robotic System, with plans for a Full Market Release (FMR) at the SIR Annual Meeting, marking a significant advancement in the medical device sector.
- Hospital Adoption: The LIBERTY system has been adopted by multiple healthcare systems, including Emory Healthcare and Tampa General Hospital, demonstrating its effectiveness and flexibility across various surgical procedures, thereby enhancing the company's competitiveness in the healthcare market.
- Sales Team Expansion: To support the FMR, the company is expanding its sales footprint from four to eight territories, with a goal of reaching twelve by the end of 2026, a strategy that will enhance market coverage and customer engagement capabilities.
- Positive Customer Feedback: High customer satisfaction and rapid adoption during the LMR indicate a shorter sales cycle compared to traditional surgical robots, which is expected to accelerate market acceptance and further drive company growth.
See More
VentriPoint Diagnostics Expands Remote Healthcare Services with AI Partnership
- Shift in Healthcare Model: Ernst & Young's 2026 outlook indicates that outpatient clinics and ambulatory services are rapidly becoming the primary growth engines of the U.S. healthcare sector, attracting significant strategic capital and prompting a realignment of healthcare infrastructure.
- AI Adoption Surge: According to NVIDIA's survey, 70% of healthcare organizations are actively deploying artificial intelligence, with over half reporting clear returns on investment from AI-powered diagnostic imaging, highlighting robust growth potential in the medical technology space.
- Innovative Partnership Model: VentriPoint's collaboration with First Light Health aims to develop a hub-and-spoke care model centered around the VMS+™ system, enabling patients in remote areas to access advanced cardiac imaging locally, reducing costs and speeding up diagnosis.
- Global Expansion Plans: Following validation of its model, VentriPoint plans to scale its services to underserved communities worldwide, showcasing its innovative capabilities in cardiac diagnostics and commitment to improving healthcare accessibility.
See More
VentriPoint Diagnostics Expands Remote Healthcare Services
- Healthcare Model Shift: Ernst & Young's 2026 outlook indicates that outpatient clinics and ambulatory services are rapidly becoming the primary growth engines of the U.S. healthcare sector, attracting significant strategic capital and prompting a realignment of healthcare infrastructure.
- AI Adoption Surge: According to NVIDIA's survey, 70% of healthcare organizations are actively deploying artificial intelligence, with over half reporting measurable returns on investment from AI-powered diagnostic imaging, highlighting a pivotal transformation in the medical technology space.
- Innovative Partnership Model: VentriPoint's collaboration with First Light Health aims to develop a hub-and-spoke care model centered around the VMS+™ system, enabling remote patients to receive cardiac ultrasound scans locally, significantly reducing costs and turnaround times, with plans to scale this model globally.
- Significant Technological Advantage: The VMS+™ system converts standard 2D echocardiograms into 3D volumetric images, achieving accuracy comparable to cardiac MRI at a fraction of the cost, which is crucial for early diagnosis in areas with high rates of heart disease and limited access to specialists, thus providing substantial social value.
See More
First Robotic Prostatic Artery Embolization Successfully Completed
- Robotic Surgery Innovation: Emory Healthcare successfully completed the first robotic Prostatic Artery Embolization (PAE) using Microbot Medical's LIBERTY System, marking a significant advancement in treating Benign Prostatic Hyperplasia (BPH) and potentially improving the quality of life for approximately 40 million men in the U.S.
- Precision Liver Cancer Treatment: Utilizing the LIBERTY System, Emory physicians performed the first Y-90 radioembolization mapping procedure, enabling personalized treatment plans for liver cancer patients, thereby enhancing treatment precision and effectiveness.
- Market Launch Strategy: Microbot Medical commenced a Limited Market Release of the LIBERTY system in November 2025, with plans for a Full Market Release at the Society of Interventional Radiology conference in April 2026, aiming to deepen market adoption and drive sales growth.
- Standardization Potential: As the only FDA-cleared single-use remotely operated robotic system, the LIBERTY System is expected to establish itself as the standard of care for PAE, similar to how robotic-assisted prostatectomy has become the dominant approach for prostate cancer treatment.
See More
Microbot Medical to Participate in Oppenheimer Healthcare Conference
- First Conference Participation: Microbot Medical will participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference from March 16-19, 2026, marking its first invitation, which reflects growing market interest and is expected to enhance the company's visibility in the healthcare sector.
- Executive Presentation: CEO Harel Gadot will present live on March 19 at 8:40 am ET, highlighting recent achievements of the LIBERTY system and key market growth drivers, aiming to accelerate customer adoption and increase shareholder value.
- Market Release Plans: The LIBERTY system commenced limited market release in late 2025, with plans for a full market launch at the Society of Interventional Radiology (SIR) conference in April 2026, showcasing its unique advantages in peripheral vascular procedures and expected to further drive market adoption.
- Strategic Investor Meetings: CFO Rachel Vaknin and VP of Strategic Marketing & Business Development Earl Adamy will meet with institutional investors on March 18, providing opportunities for one-on-one discussions with the management team, aimed at attracting more investor interest in the company's innovative technology and market potential.
See More
Microbot Medical Announces Full Market Release of LIBERTY System
- Market Release Highlights: Microbot Medical showcased the Full Market Release of its LIBERTY® Endovascular Robotic System at the 25th Annual Needham Virtual Healthcare Conference, marking a significant advancement in the medical device sector that is expected to enhance its market share and brand influence.
- CEO Presentation: CEO Harel Gadot will present live on April 15, 2026, at 10:15 AM ET, discussing the company's strategic positioning and growth opportunities, emphasizing the LIBERTY system's importance in addressing physician radiation risks and staffing challenges.
- Technological Innovation: The LIBERTY system is the world's first FDA-cleared single-use, remotely operated robotic solution designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain on physicians, which is expected to improve safety and efficiency in medical procedures.
- Investor Engagement: The Microbot team will engage in pre-scheduled one-on-one meetings with healthcare-focused institutional investors, showcasing its innovative capabilities in medical robotics and market potential, thereby attracting investor interest and driving company growth.
See More
Microbot Medical Launches LIBERTY System Successfully
- Successful Market Release: Microbot Medical announced the successful execution of its Limited Market Release (LMR) for the LIBERTY® Endovascular Robotic System, with plans for a Full Market Release (FMR) at the SIR Annual Meeting, marking a significant advancement in the medical device sector.
- Hospital Adoption: The LIBERTY system has been adopted by multiple healthcare systems, including Emory Healthcare and Tampa General Hospital, demonstrating its effectiveness and flexibility across various surgical procedures, thereby enhancing the company's competitiveness in the healthcare market.
- Sales Team Expansion: To support the FMR, the company is expanding its sales footprint from four to eight territories, with a goal of reaching twelve by the end of 2026, a strategy that will enhance market coverage and customer engagement capabilities.
- Positive Customer Feedback: High customer satisfaction and rapid adoption during the LMR indicate a shorter sales cycle compared to traditional surgical robots, which is expected to accelerate market acceptance and further drive company growth.
See More
VentriPoint Diagnostics Expands Remote Healthcare Services with AI Partnership
- Shift in Healthcare Model: Ernst & Young's 2026 outlook indicates that outpatient clinics and ambulatory services are rapidly becoming the primary growth engines of the U.S. healthcare sector, attracting significant strategic capital and prompting a realignment of healthcare infrastructure.
- AI Adoption Surge: According to NVIDIA's survey, 70% of healthcare organizations are actively deploying artificial intelligence, with over half reporting clear returns on investment from AI-powered diagnostic imaging, highlighting robust growth potential in the medical technology space.
- Innovative Partnership Model: VentriPoint's collaboration with First Light Health aims to develop a hub-and-spoke care model centered around the VMS+™ system, enabling patients in remote areas to access advanced cardiac imaging locally, reducing costs and speeding up diagnosis.
- Global Expansion Plans: Following validation of its model, VentriPoint plans to scale its services to underserved communities worldwide, showcasing its innovative capabilities in cardiac diagnostics and commitment to improving healthcare accessibility.
See More
VentriPoint Diagnostics Expands Remote Healthcare Services
- Healthcare Model Shift: Ernst & Young's 2026 outlook indicates that outpatient clinics and ambulatory services are rapidly becoming the primary growth engines of the U.S. healthcare sector, attracting significant strategic capital and prompting a realignment of healthcare infrastructure.
- AI Adoption Surge: According to NVIDIA's survey, 70% of healthcare organizations are actively deploying artificial intelligence, with over half reporting measurable returns on investment from AI-powered diagnostic imaging, highlighting a pivotal transformation in the medical technology space.
- Innovative Partnership Model: VentriPoint's collaboration with First Light Health aims to develop a hub-and-spoke care model centered around the VMS+™ system, enabling remote patients to receive cardiac ultrasound scans locally, significantly reducing costs and turnaround times, with plans to scale this model globally.
- Significant Technological Advantage: The VMS+™ system converts standard 2D echocardiograms into 3D volumetric images, achieving accuracy comparable to cardiac MRI at a fraction of the cost, which is crucial for early diagnosis in areas with high rates of heart disease and limited access to specialists, thus providing substantial social value.
See More
First Robotic Prostatic Artery Embolization Successfully Completed
- Robotic Surgery Innovation: Emory Healthcare successfully completed the first robotic Prostatic Artery Embolization (PAE) using Microbot Medical's LIBERTY System, marking a significant advancement in treating Benign Prostatic Hyperplasia (BPH) and potentially improving the quality of life for approximately 40 million men in the U.S.
- Precision Liver Cancer Treatment: Utilizing the LIBERTY System, Emory physicians performed the first Y-90 radioembolization mapping procedure, enabling personalized treatment plans for liver cancer patients, thereby enhancing treatment precision and effectiveness.
- Market Launch Strategy: Microbot Medical commenced a Limited Market Release of the LIBERTY system in November 2025, with plans for a Full Market Release at the Society of Interventional Radiology conference in April 2026, aiming to deepen market adoption and drive sales growth.
- Standardization Potential: As the only FDA-cleared single-use remotely operated robotic system, the LIBERTY System is expected to establish itself as the standard of care for PAE, similar to how robotic-assisted prostatectomy has become the dominant approach for prostate cancer treatment.
See More
Microbot Medical to Participate in Oppenheimer Healthcare Conference
- First Conference Participation: Microbot Medical will participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference from March 16-19, 2026, marking its first invitation, which reflects growing market interest and is expected to enhance the company's visibility in the healthcare sector.
- Executive Presentation: CEO Harel Gadot will present live on March 19 at 8:40 am ET, highlighting recent achievements of the LIBERTY system and key market growth drivers, aiming to accelerate customer adoption and increase shareholder value.
- Market Release Plans: The LIBERTY system commenced limited market release in late 2025, with plans for a full market launch at the Society of Interventional Radiology (SIR) conference in April 2026, showcasing its unique advantages in peripheral vascular procedures and expected to further drive market adoption.
- Strategic Investor Meetings: CFO Rachel Vaknin and VP of Strategic Marketing & Business Development Earl Adamy will meet with institutional investors on March 18, providing opportunities for one-on-one discussions with the management team, aimed at attracting more investor interest in the company's innovative technology and market potential.
See More
